Gilead Sciences has signed non-exclusive licensing deals with five generic drug makers in India and Pakistan to scale up production of remdesivir for distribution in 127 countries during the COVID-19 pandemic. The drug's price can be set by the partner companies, and no royalties will be paid to Gilead until the public health emergency is over or another drug or vaccine is approved.
Drugmakers partner with Gilead on remdesivir production
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.